购物车
- 全部删除
- 您的购物车当前为空
Anti-IGFBP4 Monoclonal Antibody-APC is a biotin-conjugated rabbit antibody targeting IGFBP4. Anti-IGFBP4 Monoclonal Antibody-APC can be used in ELISA, FACS.
Anti-IGFBP4 Monoclonal Antibody-APC is a biotin-conjugated rabbit antibody targeting IGFBP4. Anti-IGFBP4 Monoclonal Antibody-APC can be used in ELISA, FACS.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
25 μg | ¥ 779 | 7日内发货 | |
50 μg | ¥ 1,298 | 7日内发货 | |
100 μg | ¥ 1,947 | 7日内发货 |
产品描述 | Anti-IGFBP4 Monoclonal Antibody-APC is a biotin-conjugated rabbit antibody targeting IGFBP4. Anti-IGFBP4 Monoclonal Antibody-APC can be used in ELISA, FACS. |
别名 | Insulin-like growth factor-binding protein 4 |
Ig Type | Rabbit monoclonal IgG |
交叉反应 | Human |
验证活性 | Flow cytometry analysis of IGFBP4 overexpressed 442F cells with TMAZ-0372A, followed by goat anti-rabbit IgG-ABflo 647 (red line). The isotype control is rabbit IgG (black line). |
应用 | ELISA, FACS |
推荐剂量 | 0.1-0.2 μg/10E6 cells for FACS; 1 ng/μl for ELISA |
抗体种类 | Monoclonal |
宿主来源 | Rabbit |
亚细胞定位 | Secreted |
构建方式 | This antibody was produced from a rabbit immunized with purified, recombinant human extracellular domain of IGFBP4 protein. |
纯化方式 | Protein A Affinity Purified |
性状 | Liquid |
纯度 | > 95% as determined by SDS-PAGE. |
研究背景 | IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors |
其他可选修饰符 | Biotin/PE/AF488/AF555/AF647 |
可提供抗体种类 | 3 |
免疫原 | IGFBP4 |
抗原种属 | Human |
基因ID | 3487 |
Uniprot ID | |
研究领域 | Cancer Research |
分子量 | 150 kDa |
储存方式 | For unconjugated and biotin antibody, store at -20°C or -80°C for long term. Avoid repeated freeze-thaw cycles. For APC/PE/AF647/AF555/AF488 conjugated antibody, store at 4°C, do not freeze. |
运输方式 | For unconjugated and biotin antibody, shipping with dry ice. For APC/PE/AF647/AF555/AF488 conjugated antibody, shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容